Life Sciences Corporate Strategy
Evolution in the customer landscape, combined with pipeline and portfolio pressures, are presenting a range of new strategic and operational challenges for Life Sciences companies. As a result, companies should rethink their more traditional approach to the market and consider a range of new dynamics including offerings that go beyond the physical product, their presence across geographies, and other new and cost-effective growth models.
When rethinking corporate strategy, Life Sciences companies will likely be required to address the following challenges:
- The new portfolio: Generic drugs, devices from emerging markets-based manufacturers, and other disruptive market entrants challenge traditional product-based portfolio strategies
- M&A - the growth accelerator: Many Life Sciences companies are moving away from their traditional home grown R&D models and are adopting aggressive M&A and licensing strategies to quickly plug gaps left by patent expiry
- Geographic mix: Emerging markets present new opportunities for revenue and lower cost talent options
- Innovation: As cost pressures challenge traditional revenue streams, companies must redefine innovation within and around their core business to deliver differentiated value to their customers and develop new sources of revenue
As part of the Deloitte Life Sciences practice, we are able to offer a range of Corporate Strategy services and solutions to our clients. We actively collaborate with and leverage the insights of our colleagues working across the Life Sciences value chain (to maintain feasibility) and serving our Payer and Provider clients(to capture the customer’s point of view.)
|Life Sciences and emerging markets: Know your risk
Tune into the latest episode of Deloitte Insights to learn more about opportunities and risks for life sciences companies in emerging markets.
|Fortresses and footholds
Gain insight into significant revenue opportunities in emerging markets based on a survey of 628 executives.
|In pursuit of profitable growth
Understand Deloitte Consulting LLP's framework and practical advice for helping companies restructure their operating models for profitable growth in emerging markets.
|When crafting corporate strategy, should social business be bolted on or baked in?
Join the debate: Many companies recognize that social business offers new tools and rules for competing in the marketplace. But should social strategy be integrated into the overall corporate strategy, or should it stand alone?
|Breaking down the walls
Learn how to integrate clinical development with commercial operations by reading about the crisis of collaboration experienced by many pharmaceutical companies.
|The strategic cost model: Linking strategy and costs for improved decision making
Establish a foundation for meaningful analysis and reporting to help execute business strategy using Deloitte's strategic cost model.
|New growth opportunities||
|New M&A strategies||
|Emerging markets / globalization||
Meet our leadership team
Principal, Deloitte Consulting LLP
As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.